Author: admin

Dry Age-Related Macular Degeneration Pipeline Insights Report 2024 | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals

DelveInsight’s, “Dry Age-related Macular Degeneration Pipeline Insight 2024”  report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report

  • DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
  • The leading companies working in the Dry Age-Related Macular Degeneration market include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
  • Promising Dry Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
  • On January 2023, Luxa Biotechnology Inc. announced a study of Phase 1 & 2 Clinical Trials for RPESC-RPE-4W. The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
  • On August 2023, Smilebiotek Zhuhai Limited announced a study of Phase 2 Clinical Trials for QA102. This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes.

 

Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Treatment Drugs @ Dry Age-Related Macular Degeneration Pipeline Outlook Report

 

The Dry Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-Related Macular Degeneration clinical trial landscape.

 

Dry Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons.

 

Find out more about Dry Age-Related Macular Degeneration Treatment Landscape @ Drugs for Dry Age-Related Macular Degeneration Treatment

 

Dry Age-Related Macular Degeneration Emerging Drugs Profile

  • Tinlarebant (LBS-008): Belite Bio
  • XIFLAM: Inflammx Therapeutics
  • OCU410: Ocugen
  • OLX301A: OliX Pharmaceuticals
  • GS030: Gensight Biologics

 

Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The Dry Age-Related Macular Degeneration companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.

 

Learn more about the emerging Dry Age-Related Macular Degeneration Pipeline Therapies @ Dry Age-Related Macular Degeneration Clinical Trials Assessment

 

Scope of the Dry Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
  • Dry Age-Related Macular Degeneration Pipeline Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.

 

Dive deep into rich insights for new drugs for Dry Age-Related Macular Degeneration Treatment, Visit @ Dry Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dry Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dry Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Abicipar pegol: Molecular Partners
  9. Late Stage Products (Phase III)
  10. ALK-001: Alkeus Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Elamipretide: Stealth BioTherapeutics
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. AAV.sFH: Aevitas Therapeutics
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Dry Age-related Macular Degeneration Key Companies
  23. Dry Age-related Macular Degeneration Key Products
  24. Dry Age-related Macular Degeneration- Unmet Needs
  25. Dry Age-related Macular Degeneration- Market Drivers and Barriers
  26. Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
  27. Dry Age-related Macular Degeneration Analyst Views
  28. Dry Age-related Macular Degeneration Key Companies
  29. Appendix

 

For further information on the Dry Age-Related Macular Degeneration Pipeline therapeutics, reach out to Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Age-Related Macular Degeneration Pipeline Insights Report 2024 | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals

Cystic Fibrosis Pipeline Insights Report 2024 | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.

DelveInsight’s, “Cystic Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Cystic Fibrosis Pipeline Report

  • DelveInsight’s Cystic Fibrosis pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for Cystic Fibrosis treatment.
  • The leading companies working in the Cystic Fibrosis Market include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
  • Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
  • October 2023: Vertex Pharmaceuticals Incorporated announced a study of phase 3 clinical trials for ELX/TEZ/IVA and IVA. This study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (<) 24 months of age.
  • September 2023: Cystetic Medicines, Inc. announced a study of phase 1 clinical trials for ABCI. This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part B), and a Phase 1b open-label study in subjects with CF (Part C) to assess the safety, tolerability, PK, and preliminary efficacy of ABCI. Subjects will be evaluated for eligibility during Screening within 30 days before Day 1 (Randomization; Visit 3).

 

Request a sample and discover the recent advances in Cystic Fibrosis Treatment Drugs @ Cystic Fibrosis Pipeline Report

 

In the Cystic Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Cystic Fibrosis Overview

Cystic fibrosis is a progressive, genetic disease that causes long-lasting lung infections and limits the ability to breathe over time. More than 30,000 children and adults in the United States have CF (70,000 worldwide) and CF affects people of every racial and ethnic group.

 

Find out more about Cystic Fibrosis Therapeutics Assessment @ Cystic Fibrosis Preclinical and Discovery Stage Products

 

Cystic Fibrosis Emerging Drugs Profile

  • OligoG: Algi Pharma
  • Ensifentrine: Verona Pharma
  • MRT5005: Translate Bio
  • CB280: Calithera Biosciences
  • KB407 : Krystal Biotech
  • SPL84231: SpliSense

 

Cystic Fibrosis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Cystic Fibrosis therapies. The Cystic Fibrosis companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.

 

Learn more about the emerging Cystic Fibrosis Pipeline Therapies @ Cystic Fibrosis Clinical Trials Assessment

 

Scope of the Cystic Fibrosis Pipeline Report

  • Coverage- Global
  • Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Cystic Fibrosis Companies- Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxosmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
  • Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.

 

Dive deep into rich insights for new drugs for Cystic Fibrosis Treatment, Visit @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cystic Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cystic Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. OligoG : Algi pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CB280:Calithera Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SPL84231: Spli Sense
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cystic Fibrosis Key Companies
  21. Cystic Fibrosis Key Products
  22. Cystic Fibrosis Unmet Needs
  23. Cystic Fibrosis Market Drivers and Barriers
  24. Cystic Fibrosis Future Perspectives and Conclusion
  25. Cystic Fibrosis Analyst Views
  26. Cystic Fibrosis Companies
  27. Appendix

 

For further information on the Cystic Fibrosis Pipeline therapeutics, reach out to Cystic Fibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystic Fibrosis Pipeline Insights Report 2024 | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.

Revolutionizing Talent Acquisition: Scout Talent Launches Advanced Recruitment Solutions

Milton, Queensland – Scout Talent, a leading provider of recruitment software and services, announced significant updates to its platform designed to streamline recruitment processes and enhance the candidate experience.

Scout Talent’s software suite includes five key solutions. The Recruit module, designed for the talent acquisition process, is complemented by Recruitment Essentials, a lite version for small-to-medium organizations. Engage, another module, focusses on building and maintaining a talent pipeline, while Onboard simplifies and automates the onboarding process. Lastly, Scout Learning offers a customizable learning management system.

The company’s recruitment services include talent engagement, recruitment marketing and advertising, employer branding, recruitment process outsourcing, and employee engagement surveys. With its comprehensive suite of services, Scout Talent aims to identify top talent, execute and promote advertisements to attract the best candidates, and conduct strategic reviews to assess engagement levels.

In operation for the past 15 years, Scout Talent has served over 1,100 clients, with more than 7,600 monthly connected users. The company’s commitment to attracting the best talent for organizational growth, offering best-of-breed recruitment software, and providing specialist recruitment services has been pivotal to their success.

“With our open platform technology, we offer adaptable software to our clients, providing them with a streamlined recruitment process and data-driven insights,” said a spokesperson for Scout Talent. “Our AI-powered candidate matching, customizable recruitment workflows, and automated communication with candidates are just a few features that set us apart from other providers.”

Scout Talent’s platform offers numerous benefits to its clients, including improved efficiency in hiring, enhanced employer branding, and a significant reduction in time-to-fill. The platform also boasts a 20% reduction in time-to-fill, a 30% increase in quality of hires, a 15% improvement in candidate satisfaction, and a 25% cost savings in recruitment, alongside a 90% client retention rate.

“Scout Talent prides itself on its industry expertise in talent acquisition, a proven track record of successful placements, and continuous innovation in recruitment technology,” the spokesperson added. “We offer customized solutions to each client, always keeping the candidate experience at the forefront of our efforts.”

About Scout Talent:

Scout Talent is a leader in recruitment software solutions and services. With over 15 years of industry experience, the company has served more than 1,100 clients and 7,600 monthly connected users. Through its comprehensive suite of services, Scout Talent is dedicated to streamlining recruitment processes, enhancing candidate experiences, and improving hiring efficiency.

For more information about Scout Talent, please visit https://scouttalenthq.com/

Press Contact:

61 7 3330 2555

info@scouttalent.com.au

Level 1, 265 Coronation DR Milton QLD 4064

Media Contact
Company Name: Scout Talent
Email: Send Email
Phone: 61 7 3330 2555
Address:Level 1, 265 Coronation DR
City: Milton
State: Queensland
Country: Australia
Website: https://scouttalenthq.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Revolutionizing Talent Acquisition: Scout Talent Launches Advanced Recruitment Solutions

Enhanced Smiles: Introducing Fix Dental’s Advanced Dental Implant Solutions

BRISBANE, AUSTRALIA – Fix Dental, a leading dental care provider, is pleased to announce the launch of their new dental implant services, offering state-of-the-art solutions for tooth replacement. This innovation will enable patients to enjoy a permanent and natural tooth replacement option, enhancing their oral health and overall quality of life.

Dental implants are a fixed tooth replacement made from titanium and inserted into the jawbone to replace the root. On this foundation, a prosthetic tooth such as a crown or bridge is attached, which functions like a natural tooth. They offer a permanent solution that replicates natural teeth, providing a more comfortable and convenient option for patients.

In addition to conventional implants, Fix Dental is introducing keyhole implant surgery, a minimally invasive technique that provides a quick and practical solution for tooth replacement. This procedure uses state-of-the-art technology to ensure safe and precise surgery, performed by highly qualified and experienced dental teams.

“Dental implants are a game changer in oral health, providing a permanent solution for those who have lost a tooth or several teeth,” said a spokesperson for Fix Dental. “Our keyhole implant surgery further enhances this service, offering a quick and minimally invasive alternative.”

Fix Dental also offers fixed dental payment plans that come with no interest charges and allow repayment over periods of up to 12 months. A nominal administration fee of $39 is charged at the start of the plan, making these plans an ideal way to manage dental costs without any hidden surprises.

In addition to implants, Fix Dental provides an extensive range of high-quality cosmetic dentistry services. These services are offered at affordable prices, making it easier for patients to achieve a beautiful smile. Customers can book their cosmetic treatments online, enhancing the convenience of their dental care.

Fix Dental has received positive feedback from satisfied customers, highlighting the trusted and high-quality dental care offered at their multiple locations, including Brisbane and surrounding areas.

About Fix Dental

Fix Dental is a leading provider of affordable, high-quality dental services. With locations in Brisbane and surrounding areas, we are committed to providing our patients with trusted and reliable dental care. Our team of highly qualified professionals offer a variety of services, including dental implants, cosmetic dentistry, and keyhole implant surgery, all aimed at enhancing our patients’ oral health and quality of life. At Fix Dental, we believe in making dental care accessible and affordable, offering fixed dental payment plans to help our patients manage their dental costs.

Media Contact

1230 Logan Road, Mount Gravatt, QLD, Australia, Queensland

admin@fixdental.com.au

07 3520 4088

 

Media Contact
Company Name: Fix Dental
Email: Send Email
Phone: 07 3520 4088
Address:1230 Logan Road
City: Mount Gravatt
State: Queensland
Country: Australia
Website: https://www.fixdental.com.au/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Enhanced Smiles: Introducing Fix Dental\’s Advanced Dental Implant Solutions

Bringing Artistic Vision & Sporting Excellence Together: Sergey Kir Completes Commission Work for MatchPoint NYC Sports Complex

MatchPoint NYC, the leading club for sports enthusiasts, has recently commissioned artist Sergey Kir to create an art series of works that captures the essence of the luxurious lifestyle in Monaco, New York, Miami, and Aspen. The idea was to provide clients and members of MatchPoint NYC club with inspiration to work towards their own success and achievements, as well as to create a sense of belonging and exclusivity within the MatchPoint sport clubs community.

MatchPoint NYC has multiple locations and boasts state-of-the-art facilities for tennis, swimming, gymnastics, and other sports, and has earned a reputation as a premier sporting destination in New York. The addition of Kir’s exclusive artworks elevates the club’s atmosphere and gives members a glimpse into the opulent lifestyles in the world’s best destinations.

 

Kir is a rising star in the art world, with his works held in multiple collections and museums. His unique approach to capturing the essence of his subjects has made him a highly sought-after artist, and his ability to convey different ideas and visions of his patrons made him a great choice for MatchPoint’s commission.

“We are thrilled to have Sergey Kir’s artwork grace the walls of our club,” said MatchPoint’s Managing Partner Numrud  Nino Muhatasov. “We know our members will be inspired by his work every time they visit our facility.”

“I am honored to have had the opportunity to work with MatchPoint club’s co-founder Nino Muhatasov on this commission. His commitment to providing top-of-the-line facilities and aesthetic atmosphere for sports enthusiasts is unparalleled, and I am thrilled to have been able to contribute to that mission by bringing Mr. Muhatasov’s visions to life in the exclusive art series of works made for the club. I hope my art will inspire and delight MatchPoint’s club members for years to come.”

 

Fashionable Trend 

Premiere sport brands like MatchPoint, as well as other major fashion and technology brands, often collaborate with artists and incorporate art into their products to promote and enhance their brand image. Here are some examples:

1. LV x Jeff Koons collaboration – In 2017, LV collaborated with renowned artist Jeff Koons to create a limited-edition collection of bags, scarves, and accessories.

2. Gucci x Dapper Dan – In 2017, Gucci collaborated with Harlem-based designer Dapper Dan to create a collection inspired by his iconic designs from the 1980s.

3. Prada Fondazione – Prada has its own art foundation, the Prada Fondazione, which aims to promote contemporary art and culture, and hosts exhibitions, installations, and events.

4. Apple x Jeff Koons – Apple collaborated with Jeff Koons to create a line of iPhone cases featuring Koons’ artwork.

5. Adidas x Pharrell Williams – Pharrell Williams, a popular artist, collaborated with Adidas to create a line of sneakers and apparel.

Such collaborations can help promote the brands as creative, innovative, and culturally aware, while also showcasing their unique styles and creating strong emotional connections with their audience. In addition, such collaborations can generate excitement and buzz around the products and services and increase consumer interest and loyalty.

For artists, collaborating with sports, fashion, and other brands can provide greater exposure, creative opportunities, social impact, and professional development. These benefits can help artists expand their reach, develop their skills and networks, and create meaningful and impactful work.

About Sergey Kir

Sergey Kir is an innovative artist who has created his own remarkable,new art style, which was coined “Conceptivism.” An ambitious approach to painting, Conceptivism synthesizes technology, art history, analytical methods adopted from quantitative finance.

Kir’s compositions are planned using computer algorithms, with strong philosophical messages.

Kir has exhibited his diverse body of works in various galleries and shows, with his creations gracing both private and corporate collections.

In a groundbreaking move, recently Kir introduced his “Art Your Journey” limited edition print series, which he presented via art exhibitions on fashion runways in collaboration with leading fashion brands (EX)teasy Lingeire and Donny’s Angel. This innovative fusion of Art and Fashion and a new way to showcase art on vibrant runways, earned widespread critical acclaim,  and a viral response across platforms like YouTube and other social media channels.

Kir is scheduled to hold an art retrospective and unveiling of the “Art Your Journey” series at the prestigious Canvas 3.0 gallery in the NY World Trade Center on February 22nd. https://www.eventbrite.com/e/823315277157?aff=ebdsshios

To purchase the limited edition prints “Art Your Journey”, please visit https://kirgallery.com 

Kir’s viral Art and Fashion show (produced by Fashion Stock TV): https://youtu.be/HO4qq8HxFh4?si=SutNeeZupsC_q-dx

About MatchPoint NYC

MatchPoint NYC Clubs are a fitness and sports courts. Come in and reinvent yourself at one of our spacious facilities.

Contact MatchPoint NYC club:

Phone: 718-769-0001

Website: https://matchpoint.nyc/

 

Media Contact
Company Name: Conceptivism Technologies LLC
Contact Person: Daniel Kireyev
Email: Send Email
City: Brooklyn
State: NY
Country: United States
Website: www.kirgallery.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bringing Artistic Vision & Sporting Excellence Together: Sergey Kir Completes Commission Work for MatchPoint NYC Sports Complex

Roofer Digest Unveils the Top 12 Roofing Trends for 2024

February 19, 2024 – Roofer Digest, a leading authority in the roofing industry, has released an expert roundup detailing the top 12 roofing trends to watch in 2024. This comprehensive analysis provides insights into the future of roofing, highlighting the shift towards sustainability, technological advancements, and material innovation.

Key Insights from the Report:

  • Sustainability and Eco-Friendliness: A significant move towards adaptive roofing materials and solar solutions emphasizes the industry’s commitment to reducing environmental impact.
  • Technological Integration: The use of AI, drones, and augmented reality for inspections and customer interactions is revolutionizing roofing practices.
  • Material Innovation: There’s a growing preference for durable, long-lasting materials, with synthetic and solar roofing options gaining popularity.


Highlights:

  • Adaptive Roofing Materials: Innovations such as smart materials and nanotechnology are set to enhance durability and energy efficiency.
  • Reflective Surfaces: Materials designed to reflect heat away from buildings are reducing cooling costs and extending roof lifespan.
  • Virtual Inspections: The adoption of virtual inspections offers a safer and more efficient alternative to traditional methods.
  • Aesthetic and Functional Synergy: The demand for roofing that combines visual appeal with functionality is on the rise, with neutral color palettes and eco-friendly options becoming popular.
  • Regulatory and Code Enhancements: Updates to building codes are expected to mandate the implementation of hurricane-resistant and fire-resistant roofing systems.


About Roofer Digest:

Roofer Digest is a premier online platform dedicated to providing the latest news, trends, and insights in the roofing industry. With a focus on innovation, sustainability, and best practices, Roofer Digest serves as a valuable resource for professionals and homeowners alike.

For more information visit https://rooferdigest.com/

Media Contact
Company Name: Roofer Digest
Contact Person: Dan R. Reynolds
Email: Send Email
Country: United States
Website: https://rooferdigest.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Roofer Digest Unveils the Top 12 Roofing Trends for 2024

Laser Vision SA Revolutionizes Vision Correction with Advanced Laser Eye Surgery

Adelaide – Laser Vision SA, the leading provider of laser vision correction in Adelaide, is proud to offer unparalleled support, expert advice, and state-of-the-art technology to help individuals achieve their best vision without the need for glasses or contacts. With a commitment to excellence and a track record of success, Laser Vision SA is revolutionizing the way people see the world.

As Adelaide’s most experienced laser vision correction clinic, Laser Vision SA brings a wealth of expertise and knowledge to the table. Offering a comprehensive range of options, including All Laser LASIK and the cutting-edge SMILE Pro procedure, they empower individuals to take control of their vision and experience the freedom of clear sight.

“When it comes to Laser Eye Surgery, we understand the desire to wake up and see without the ongoing discomfort, inconvenience, and costs of glasses or contacts. We believe that everyone deserves to experience life with 21st-century technology and the confidence that comes with a skilled and dedicated team,” said Dr Fraenkel, the renowned laser eye surgeon at Laser Vision SA. “That’s why we’re committed to providing our patients with the best possible care, backed by our extensive experience and the latest advancements in laser vision correction.”

Dr Fraenkel, the pioneer in the field of laser eye surgery, was the first to introduce ALL Laser LASIK in 2012, followed by SMILE in 2014 and the revolutionary SMILE Pro in 2022. With a record number of successful SMILE procedures under his belt, Dr Fraenkel’s expertise is unparalleled. In fact, his commitment to his craft is so unwavering that he has personally undergone the SMILE procedure himself, a testament to the trust he places in his own work.

Embarking on the journey to visual freedom with Laser Vision SA is a four-step process that is shorter, simpler, and more comfortable than one might expect. With no referral required, individuals can take control of their vision with confidence:

  1. Diagnostic tests: Laser Vision SA’s diagnostic tests help determine the most suitable vision correction method for each individual’s unique needs.

  2. Consultation: A consultation with the experienced team at Laser Vision SA allows for a comprehensive discussion about specific requirements and the best vision correction solutions available.

  3. Treatment: The vision correction procedure is a simple day procedure tailored to the individual’s preferences and needs.

  4. Review: Follow-up appointments are conducted one day and one month after the vision correction procedure to ensure optimal results and address any concerns.

Laser Vision SA’s commitment to excellence extends to their dedication to helping as many people as possible. They proudly offer laser vision correction solutions for individuals who are short-sighted, long-sighted, have astigmatism, or require reading glasses. With a success rate of 98% among patients wearing glasses or contacts, Laser Vision SA has the expertise to guide individuals towards the best vision correction technologies and support them every step of the way.

“While vision correction is an investment, we firmly believe that the long-term benefits far outweigh the costs. When you consider the ongoing expenses of glasses and contacts, as well as the priceless value of restoring your vision and achieving freedom from optical aids, laser eye surgery becomes a worthwhile investment,” added Dr Fraenkel.

To take the first steps towards visual freedom, individuals are invited to fill out an enquiry form or call Laser Vision SA directly at 08 8359 2422.

For more information about Laser Vision SA and their cutting-edge laser eye surgery options, please visit their website at https://laservisionsa.com.au/

About Laser Vision SA:

Laser Vision SA is Adelaide’s leading provider of laser vision correction procedures, offering the most advanced technologies to help individuals achieve their best vision without the need for glasses.

Media Contact
Company Name: Laser Vision SA
Email: Send Email
Phone: (08) 8359 2422
Address:Ground Floor, 169 Pirie Street
City: Adelaide
State: SA 5000
Country: Australia
Website: https://laservisionsa.com.au/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Laser Vision SA Revolutionizes Vision Correction with Advanced Laser Eye Surgery

Seasonal Influenza Market, Epidemiology, Clinical Trials and FDA Approvals DelveInsight | Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics

“Seasonal Influenza Market”

(Albany, USA) DelveInsight’s “Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Seasonal Influenza market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Seasonal Influenza market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Seasonal Influenza treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Seasonal Influenza market.

 

Request for a Free Sample Report @ Seasonal Influenza Market Forecast

 

Some facts of Seasonal Influenza market report:

  • In 2021, the total vaccinated population estimated to be 366,474,828 in the 7MM. Highest vaccinated population was seen in the US.
  • In Japan, 8,105 medical visits related to seasonal influenza were estimated in 2021, which are expected to decline during the forecasted period (2023-2032).
  • In the assessment done by DelveInsight, the estimated total medical visits related to seasonal influenza in the 7MM were 11,235,325 in 2021.
  • The Seasonal Influenza therapeutic market size in the 7MM was USD 6,646 million in 2021.
  • Several companies are trying their hand in the developmental pipeline of seasonal influenza to address some unmet needs and gain bundles of market opportunities. The pipeline projects are focused on the prevention and treatment of the flu.
  • Some of the seasonal influenza companies working in the market are SAb Biotherapeutics, Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, NanoViricides, Evrys Bio, ETHRIS, Kino Pharma and others.

 

Seasonal Influenza Overview

Seasonal influenza is an acute viral infection that spreads easily from person to person, causing annual epidemics which peak during the winter in temperate regions of the world. There are four types of influenza viruses: influenza A, B, C, and D, but only influenza A and B viruses cause clinically important human diseases and seasonal epidemics.

 

Learn more about Seasonal Influenza treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/seasonal-influenza-market

 

Seasonal Influenza Market

The Seasonal Influenza market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Seasonal Influenza market trends by analyzing the impact of current Seasonal Influenza therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Seasonal Influenza market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Seasonal Influenza market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Seasonal Influenza market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Seasonal Influenza Epidemiology

The Seasonal Influenza epidemiology section provides insights into the historical and current Seasonal Influenza patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Seasonal Influenza market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Seasonal Influenza Epidemiology @ Seasonal Influenza Market Dynamics

 

Seasonal Influenza Drugs Uptake

This section focuses on the uptake rate of the potential Seasonal Influenza drugs recently launched in the Seasonal Influenza market or expected to be launched in 2019-2032. The analysis covers the Seasonal Influenza market uptake by drugs, patient uptake by therapies, and sales of each drug.

Seasonal Influenza Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Seasonal Influenza market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Seasonal Influenza Pipeline Development Activities

The Seasonal Influenza report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Seasonal Influenza key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Seasonal Influenza pipeline development activities @ https://www.delveinsight.com/sample-request/seasonal-influenza-market

 

Seasonal Influenza Therapeutics Assessment

Major key companies are working proactively in the Seasonal Influenza Therapeutics market to develop novel therapies which will drive the Seasonal Influenza treatment markets in the upcoming years are SAb Biotherapeutics, Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, NanoViricides, Evrys Bio, ETHRIS, Kino Pharma and others.

 

Learn more about the emerging Seasonal Influenza therapies & key companies @ https://www.delveinsight.com/sample-request/seasonal-influenza-market

 

Seasonal Influenza Report Key Insights

1. Seasonal Influenza Patient Population

2. Seasonal Influenza Market Size and Trends

3. Key Cross Competition in the Seasonal Influenza Market

4. Seasonal Influenza Market Dynamics (Key Drivers and Barriers)

5. Seasonal Influenza Market Opportunities

6. Seasonal Influenza Therapeutic Approaches

7. Seasonal Influenza Pipeline Analysis

8. Seasonal Influenza Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Seasonal Influenza Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Seasonal Influenza Competitive Intelligence Analysis

4. Seasonal Influenza Market Overview at a Glance

5. Seasonal Influenza Disease Background and Overview

6. Seasonal Influenza Patient Journey

7. Seasonal Influenza Epidemiology and Patient Population

8. Seasonal Influenza Treatment Algorithm, Current Treatment, and Medical Practices

9. Seasonal Influenza Unmet Needs

10. Key Endpoints of Seasonal Influenza Treatment

11. Seasonal Influenza Marketed Products

12. Seasonal Influenza Emerging Therapies

13. Seasonal Influenza Seven Major Market Analysis

14. Attribute Analysis

15. Seasonal Influenza Market Outlook (7 major markets)

16. Seasonal Influenza Access and Reimbursement Overview

17. KOL Views on the Seasonal Influenza Market

18. Seasonal Influenza Market Drivers

19. Seasonal Influenza Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Seasonal Influenza Market, Epidemiology, Clinical Trials and FDA Approvals DelveInsight | Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics

Secondary Hyperparathyroidism Market, Epidemiology, Clinical Trials and FDA Approvals by DelveInsight | Amgen, OPKO Health, AbbVie, Shire, Roche, Sanofi, Kyowa Hakko Kirin, Astellas Pharma, Leo Pharma

“Secondary Hyperparathyroidism Market”

(New York, USA) DelveInsight’s “Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Secondary Hyperparathyroidism market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Secondary Hyperparathyroidism market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Secondary Hyperparathyroidism treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Secondary Hyperparathyroidism market.

 

Request for a Free Sample Report @ Secondary Hyperparathyroidism Market Forecast

 

Some facts of the Secondary Hyperparathyroidism Market Report are:

  • According to DelveInsight, Secondary Hyperparathyroidism market size is expected to grow at a decent CAGR by 2032.
  • Leading Secondary Hyperparathyroidism companies working in the market are Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, Shanghai Hengrui Pharmaceutical Co., Ltd, KAI Pharmaceuticals, Abbott, Sanwa Kagaku Kenkyusho Co., Deltanoid Pharmaceuticals and others.
  • Key Secondary Hyperparathyroidism Therapies expected to launch in the market are KHK7580, Cinacalcet Hydrochloride, Etelcalcetide, ASP7991, SHR6508, Dose-adjusted SK-1403, DP001, Sensipar, Paricalcitol, Doxercalciferol (GZ427397), Sensipar, and others.

 

Secondary Hyperparathyroidism Overview

Secondary hyperparathyroidism is a medical condition that occurs as a result of chronic kidney disease (CKD) or other conditions that lead to prolonged imbalances in calcium and phosphorus levels in the body. It involves the overactivity of the parathyroid glands, which are responsible for regulating calcium and phosphorus metabolism. Secondary hyperparathyroidism primarily occurs as a compensatory response to imbalances in calcium and phosphorus metabolism, commonly associated with chronic kidney disease. In CKD, the kidneys are unable to effectively regulate calcium and phosphorus levels, resulting in low calcium and high phosphorus levels. As a result, the parathyroid glands produce excessive PTH to maintain calcium balance, leading to hyperparathyroidism.

 

Learn more about Secondary Hyperparathyroidism treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/secondary-hyperparathyroidism-market

 

Secondary Hyperparathyroidism Market 

The Secondary Hyperparathyroidism market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Secondary Hyperparathyroidism market trends by analyzing the impact of current Secondary Hyperparathyroidism therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Secondary Hyperparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Secondary Hyperparathyroidism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Secondary Hyperparathyroidism market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Secondary Hyperparathyroidism Epidemiology

The Secondary Hyperparathyroidism epidemiology section provides insights into the historical and current Secondary Hyperparathyroidism patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Secondary Hyperparathyroidism market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Secondary Hyperparathyroidism Epidemiology @ https://www.delveinsight.com/sample-request/secondary-hyperparathyroidism-market

 

Secondary Hyperparathyroidism Drugs Uptake

This section focuses on the uptake rate of the potential Secondary Hyperparathyroidism drugs recently launched in the Secondary Hyperparathyroidism market or expected to be launched in 2019-2032. The analysis covers the Secondary Hyperparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Secondary Hyperparathyroidism Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Secondary Hyperparathyroidism market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Secondary Hyperparathyroidism Pipeline Development Activities

The Secondary Hyperparathyroidism report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Secondary Hyperparathyroidism key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Secondary Hyperparathyroidism pipeline development activities @ https://www.delveinsight.com/sample-request/secondary-hyperparathyroidism-market

 

Secondary Hyperparathyroidism Therapeutics Assessment

Major key companies are working proactively in the Secondary Hyperparathyroidism Therapeutics market to develop novel therapies which will drive the Secondary Hyperparathyroidism treatment markets in the upcoming years are Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, Shanghai Hengrui Pharmaceutical Co., Ltd, KAI Pharmaceuticals, Abbott, Sanwa Kagaku Kenkyusho Co., Deltanoid Pharmaceuticals and others.

 

Learn more about the emerging Secondary Hyperparathyroidism therapies & key companies @ https://www.delveinsight.com/sample-request/secondary-hyperparathyroidism-market

 

Secondary Hyperparathyroidism Report Key Insights

1. Secondary Hyperparathyroidism Patient Population

2. Secondary Hyperparathyroidism Market Size and Trends

3. Key Cross Competition in the Secondary Hyperparathyroidism Market

4. Secondary Hyperparathyroidism Market Dynamics (Key Drivers and Barriers)

5. Secondary Hyperparathyroidism Market Opportunities

6. Secondary Hyperparathyroidism Therapeutic Approaches

7. Secondary Hyperparathyroidism Pipeline Analysis

8. Secondary Hyperparathyroidism Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Secondary Hyperparathyroidism Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Secondary Hyperparathyroidism Competitive Intelligence Analysis

4. Secondary Hyperparathyroidism Market Overview at a Glance

5. Secondary Hyperparathyroidism Disease Background and Overview

6. Secondary Hyperparathyroidism Patient Journey

7. Secondary Hyperparathyroidism Epidemiology and Patient Population

8. Secondary Hyperparathyroidism Treatment Algorithm, Current Treatment, and Medical Practices

9. Secondary Hyperparathyroidism Unmet Needs

10. Key Endpoints of Secondary Hyperparathyroidism Treatment

11. Secondary Hyperparathyroidism Marketed Products

12. Secondary Hyperparathyroidism Emerging Therapies

13. Secondary Hyperparathyroidism Seven Major Market Analysis

14. Attribute Analysis

15. Secondary Hyperparathyroidism Market Outlook (7 major markets)

16. Secondary Hyperparathyroidism Access and Reimbursement Overview

17. KOL Views on the Secondary Hyperparathyroidism Market

18. Secondary Hyperparathyroidism Market Drivers

19. Secondary Hyperparathyroidism Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Secondary Hyperparathyroidism Market, Epidemiology, Clinical Trials and FDA Approvals by DelveInsight | Amgen, OPKO Health, AbbVie, Shire, Roche, Sanofi, Kyowa Hakko Kirin, Astellas Pharma, Leo Pharma

Schizophrenia Market and Epidemiology Analysis 2032: DelveInsight | Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion, Otsuka Pharmaceuticals

“Schizophrenia Market”

(New York, USA) DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Schizophrenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Schizophrenia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Schizophrenia market.

 

Request for a Free Schizophrenia Sample Report @ Schizophrenia Market Forecast

 

Some facts of the Schizophrenia Market Report are:

  • According to DelveInsight, Schizophrenia market size was USD 8,664.6 million in 2021.
  • Leading Schizophrenia companies working in the market are Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
  • Promising Schizophrenia Therapies are Ulotaront, Luvadaxistat, CY6463 and many others.
  • In the year 2021, the total prevalent cases of Schizophrenia were 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

Schizophrenia Overview

Schizophrenia causes psychosis and is associated with considerable disability and may affect all areas of life including personal, family, social, educational, and occupational functioning. It is thought that an interaction between genes and a range of environmental factors may cause schizophrenia. Psychosocial factors may also affect the onset and course of schizophrenia. Heavy use of cannabis is associated with an elevated risk of the disorder.

Schizophrenia is characterized by significant impairments in the way reality is perceived and changes in behaviour related to: Persistent delusions, persistent hallucinations, experiences of influence, control or passivity, disorganized thinking, highly disorganized behavior, “negative symptoms” such as very limited speech, extreme agitation or slowing of movements etc.

Diagnosis of schizophrenia is reached through an assessment of patient-specific signs and symptoms like delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Schizophrenia Treatment is usually lifelong and often involves a combination of medications, psychotherapy and coordinated speciality care services.

 

Learn more about Schizophrenia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/schizophrenia-market

 

Schizophrenia Market 

The Schizophrenia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Schizophrenia market trends by analyzing the impact of current Schizophrenia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Schizophrenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Schizophrenia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Schizophrenia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Schizophrenia Epidemiology 

The Schizophrenia epidemiology section provides insights into the historical and current Schizophrenia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Schizophrenia market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Schizophrenia Epidemiology @ Schizophrenia Market Dynamics

 

Schizophrenia Drugs Uptake

This section focuses on the uptake rate of the potential Schizophrenia drugs recently launched in the Schizophrenia market or expected to be launched in 2019-2032. The analysis covers the Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Schizophrenia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Schizophrenia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Schizophrenia Pipeline Development Activities

The Schizophrenia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Schizophrenia key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Schizophrenia pipeline development activities @ https://www.delveinsight.com/sample-request/schizophrenia-market

 

Schizophrenia Therapeutics Assessment

Major key companies are working proactively in the Schizophrenia Therapeutics market to develop novel therapies which will drive the Schizophrenia treatment markets in the upcoming years are Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.

 

Learn more about the emerging Schizophrenia therapies & key companies @ https://www.delveinsight.com/sample-request/schizophrenia-market

 

Schizophrenia Report Key Insights

1. Schizophrenia Patient Population

2. Schizophrenia Market Size and Trends

3. Key Cross Competition in the Schizophrenia Market

4. Schizophrenia Market Dynamics (Key Drivers and Barriers)

5. Schizophrenia Market Opportunities

6. Schizophrenia Therapeutic Approaches

7. Schizophrenia Pipeline Analysis

8. Schizophrenia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Schizophrenia Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Schizophrenia Competitive Intelligence Analysis

4. Schizophrenia Market Overview at a Glance

5. Schizophrenia Disease Background and Overview

6. Schizophrenia Patient Journey

7. Schizophrenia Epidemiology and Patient Population

8. Schizophrenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Schizophrenia Unmet Needs

10. Key Endpoints of Schizophrenia Treatment

11. Schizophrenia Marketed Products

12. Schizophrenia Emerging Therapies

13. Schizophrenia Seven Major Market Analysis

14. Attribute Analysis

15. Schizophrenia Market Outlook (7 major markets)

16. Schizophrenia Access and Reimbursement Overview

17. KOL Views on the Schizophrenia Market

18. Schizophrenia Market Drivers

19. Schizophrenia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Market and Epidemiology Analysis 2032: DelveInsight | Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion, Otsuka Pharmaceuticals